Literature DB >> 17342666

Current controversies in the management of adult syphilis.

Bradley P Stoner1.   

Abstract

Clinical management of patients with syphilis is controversial. This article summarizes recent research on syphilis treatment efficacy and outcomes and is based on a comprehensive systematic review of published literature, relevant abstracts, conference proceedings, technical reports, and guidelines. Penicillin remains the drug of choice for the treatment of syphilis. Although several studies have suggested that azithromycin may have clinical efficacy, macrolide resistance has been widely documented among strains of Treponema pallidum, and treatment failures have been reported. Ceftriaxone is effective for the treatment of syphilis when used in multiple-dose regimens. Lumbar puncture should be performed for human immunodeficiency virus-infected patients with syphilis of >1 year's duration and a serum nontreponemal test titer > or =1 : 32, as well for other patients for whom the clinical suspicion of neurosyphilis is high. Newer laboratory tests for syphilis are undergoing extensive evaluation and may prove to be useful for future clinical care. American and European approaches to syphilis treatment are similar, but they vary across several parameters.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17342666     DOI: 10.1086/511426

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Recent trends in the serologic diagnosis of syphilis.

Authors:  Muhammad G Morshed; Ameeta E Singh
Journal:  Clin Vaccine Immunol       Date:  2014-11-26

2.  Neurosyphilis masquerading as hemiparesis and Jacksonian epilepsy in an HIV positive patient: a case report.

Authors:  P S Kyebambe
Journal:  Afr Health Sci       Date:  2010-06       Impact factor: 0.927

3.  Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda.

Authors:  Jodie Dionne-Odom; Etienne Karita; William Kilembe; Faith Henderson; Bellington Vwalika; Roger Bayingana; Zhigang Li; Joseph Mulenga; Elwyn Chomba; Carlos Del Rio; Naw Htee Khu; Amanda Tichacek; Susan Allen
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

4.  Detection of the A2058G and A2059G 23S rRNA gene point mutations associated with azithromycin resistance in Treponema pallidum by use of a TaqMan real-time multiplex PCR assay.

Authors:  Cheng-Yen Chen; Kai-Hua Chi; Allan Pillay; Eli Nachamkin; John R Su; Ronald C Ballard
Journal:  J Clin Microbiol       Date:  2013-01-02       Impact factor: 5.948

5.  Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin.

Authors:  Arlene C Seña; Mark Wolff; Frieda Behets; Kathleen Van Damme; David H Martin; Peter Leone; Linda McNeil; Edward W Hook
Journal:  Clin Infect Dis       Date:  2012-11-01       Impact factor: 9.079

Review 6.  Global challenge of antibiotic-resistant Treponema pallidum.

Authors:  Lola V Stamm
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

7.  Ocular manifestations of syphilis: recent cases over a 2.5-year period.

Authors:  Cindy Puech; Stéphane Gennai; Patricia Pavese; Isabelle Pelloux; Max Maurin; Jean-Paul Romanet; Christophe Chiquet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-12       Impact factor: 3.535

Review 8.  Lives Saved Tool supplement detection and treatment of syphilis in pregnancy to reduce syphilis related stillbirths and neonatal mortality.

Authors:  Hannah Blencowe; Simon Cousens; Mary Kamb; Stuart Berman; Joy E Lawn
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

9.  Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone.

Authors:  Petra Spornraft-Ragaller; S Abraham; C Lueck; M Meurer
Journal:  Eur J Med Res       Date:  2011-02-24       Impact factor: 2.175

10.  An estimate of syphilis incidence in Eastern Europe.

Authors:  Liam J Herbert; Stephen I Middleton
Journal:  J Glob Health       Date:  2012-06       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.